• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

局部晚期前列腺癌根治性前列腺切除术与放疗联合雄激素剥夺治疗的倾向评分匹配分析。

Propensity score matching analysis comparing radical prostatectomy and radiotherapy with androgen deprivation therapy in locally advanced prostate cancer.

机构信息

Department of Urology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan.

Division of Radiation Oncology, Department of Oncology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan.

出版信息

Sci Rep. 2022 Jul 21;12(1):12480. doi: 10.1038/s41598-022-16700-7.

DOI:10.1038/s41598-022-16700-7
PMID:35864293
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9304348/
Abstract

To compare clinical outcomes between the use of robotic-assisted laparoscopic radical prostatectomy (RP) and radiotherapy (RT) with long-term androgen deprivation therapy (ADT) in locally advanced prostate cancer (PC), 315 patients with locally advanced PC (clinical T-stage 3/4) were considered for analysis retrospectively. Propensity score-matching at a 1:1 ratio was performed. The median follow-up period was 59.2 months (IQR 39.8-87.4). There were 117 (37.1%) patients in the RP group and 198 (62.9%) patients in the RT group. RT patients were older and had higher PSA at diagnosis, higher Gleason score grade group and more advanced T-stage (all p < 0.001). After propensity score-matching, there were 68 patients in each group. Among locally advanced PC patients, treatment with RP had a higher risk of biochemical recurrence compared to the RT group. In multivariate Cox regression analysis, treatment with RT plus ADT significantly decreased the risk of biochemical failure (HR 0.162, p < 0.001), but there was no significant difference in local recurrence, distant metastasis and overall survival (p = 0.470, p = 0.268 and p = 0.509, respectively). This information supported a clinical benefit in BCR control for patients undergoing RT plus long-term ADT compared to RP.

摘要

为了比较机器人辅助腹腔镜前列腺癌根治术(RP)与放射治疗(RT)联合长期雄激素剥夺疗法(ADT)治疗局部进展性前列腺癌(PC)的临床结局,回顾性分析了 315 例局部进展性 PC(临床 T 期 3/4 期)患者。采用 1:1 比例的倾向评分匹配法。中位随访时间为 59.2 个月(IQR 39.8-87.4)。RP 组 117 例(37.1%),RT 组 198 例(62.9%)。RT 组患者年龄较大,诊断时 PSA 较高,Gleason 评分较高,T 期较晚(均 P<0.001)。经过倾向评分匹配后,每组各有 68 例患者。在局部进展性 PC 患者中,与 RT 组相比,RP 治疗的生化复发风险更高。多因素 Cox 回归分析显示,RT 联合 ADT 治疗可显著降低生化失败风险(HR 0.162,P<0.001),但局部复发、远处转移和总生存无显著差异(P=0.470,P=0.268 和 P=0.509)。这些信息支持 RT 联合长期 ADT 治疗在 BCR 控制方面优于 RP。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d82/9304348/4cb434e19593/41598_2022_16700_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d82/9304348/a9566b6c134f/41598_2022_16700_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d82/9304348/6585c863be50/41598_2022_16700_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d82/9304348/478f417df832/41598_2022_16700_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d82/9304348/4cb434e19593/41598_2022_16700_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d82/9304348/a9566b6c134f/41598_2022_16700_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d82/9304348/6585c863be50/41598_2022_16700_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d82/9304348/478f417df832/41598_2022_16700_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d82/9304348/4cb434e19593/41598_2022_16700_Fig4_HTML.jpg

相似文献

1
Propensity score matching analysis comparing radical prostatectomy and radiotherapy with androgen deprivation therapy in locally advanced prostate cancer.局部晚期前列腺癌根治性前列腺切除术与放疗联合雄激素剥夺治疗的倾向评分匹配分析。
Sci Rep. 2022 Jul 21;12(1):12480. doi: 10.1038/s41598-022-16700-7.
2
Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy.根治性前列腺切除术和辅助放疗后前列腺癌患者接受雄激素剥夺治疗的最佳 PSA 阈值。
Yonsei Med J. 2020 Aug;61(8):652-659. doi: 10.3349/ymj.2020.61.8.652.
3
Long-term follow-up comparing salvage radiation therapy and androgen-deprivation therapy for biochemical recurrence after radical prostatectomy.根治性前列腺切除术后生化复发后挽救性放疗与雄激素剥夺治疗的长期随访比较。
Int J Clin Oncol. 2021 Apr;26(4):744-752. doi: 10.1007/s10147-020-01839-y. Epub 2021 Jan 2.
4
Impact of Early Salvage Androgen Deprivation Therapy in Localized Prostate Cancer after Radical Prostatectomy: A Propensity Score Matched Analysis.早期挽救性雄激素剥夺疗法对前列腺癌根治术后局限性前列腺癌的影响:一项倾向评分匹配分析
Yonsei Med J. 2018 Jul;59(5):580-587. doi: 10.3349/ymj.2018.59.5.580.
5
Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series.早期挽救性放疗后生化复发的前列腺癌患者应用同期雄激素剥夺治疗:一项大型多机构系列研究的长期结果。
Eur Urol. 2018 Apr;73(4):512-518. doi: 10.1016/j.eururo.2017.11.020. Epub 2017 Dec 8.
6
Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy.雄激素剥夺治疗持续时间对接受根治性前列腺切除术后放射治疗的患者结局的影响。
Eur Urol. 2016 Jan;69(1):50-7. doi: 10.1016/j.eururo.2015.05.009. Epub 2015 May 21.
7
Radiotherapy plus androgen deprivation therapy for prostate-specific antigen persistence in lymph node-positive prostate cancer.放化疗联合雄激素剥夺疗法治疗淋巴结阳性前列腺癌中前列腺特异抗原持续存在。
Cancer Sci. 2022 Jul;113(7):2386-2396. doi: 10.1111/cas.15383. Epub 2022 May 17.
8
Cancer-Specific Mortality Among Korean Men with Localized or Locally Advanced Prostate Cancer Treated with Radical Prostatectomy Versus Radiotherapy: A Multi-Center Study Using Propensity Scoring and Competing Risk Regression Analyses.根治性前列腺切除术与放疗治疗局限性或局部进展性前列腺癌的韩国男性患者的癌症特异性死亡率:使用倾向评分和竞争风险回归分析的多中心研究。
Cancer Res Treat. 2018 Jan;50(1):129-137. doi: 10.4143/crt.2017.004. Epub 2017 Mar 8.
9
Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above.活检Gleason评分8分及以上的局限性前列腺癌患者前列腺切除术后或放疗后的复发率影响因素。
Cancer. 2002 Dec 1;95(11):2302-7. doi: 10.1002/cncr.10977.
10
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.EAU 前列腺癌指南。第二部分:晚期、复发性和去势抵抗性前列腺癌的治疗。
Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12.

引用本文的文献

1
Efficacy and safety of neoadjuvant chemohormonal therapy for high-risk prostate cancer treated with robot-assisted laparoscopic radical prostatectomy: a propensity score-matched analysis (the MSUG94 group).新辅助化疗激素疗法联合机器人辅助腹腔镜根治性前列腺切除术治疗高危前列腺癌的疗效与安全性:倾向评分匹配分析(MSUG94组)
Int Urol Nephrol. 2025 Mar;57(3):809-816. doi: 10.1007/s11255-024-04268-2. Epub 2024 Nov 8.
2
Overall Survival and Cancer-Specific Mortality in Patients with Prostate Cancer Undergoing Definitive Therapies: A Narrative Review.接受确定性治疗的前列腺癌患者的总生存期和癌症特异性死亡率:一项叙述性综述
J Clin Med. 2024 Sep 19;13(18):5561. doi: 10.3390/jcm13185561.
3

本文引用的文献

1
Dose-escalated pelvic radiotherapy for prostate cancer in definitive or postoperative setting.在根治性或术后情况下,对前列腺癌进行剂量递增的盆腔放疗。
Radiol Med. 2022 Feb;127(2):206-213. doi: 10.1007/s11547-021-01435-8. Epub 2021 Nov 30.
2
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020:全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
3
Application of Radiomics for the Prediction of Radiation-Induced Toxicity in the IMRT Era: Current State-of-the-Art.
Combination approach using neoadjuvant therapy with radical prostatectomy for improving oncological outcomes of high-risk prostate cancer: a narrative review.
采用新辅助治疗联合根治性前列腺切除术改善高危前列腺癌肿瘤学结局的综合方法:一项叙述性综述
Transl Cancer Res. 2024 Jul 31;13(7):3889-3897. doi: 10.21037/tcr-23-2394. Epub 2024 Jul 8.
4
Assessing the Efficacy and Long-Term Outcomes of Surgical Intervention Versus Radiotherapy: A Comprehensive Systematic Review and Meta-Analysis of Prostate Cancer Treatment Modalities.评估手术干预与放疗的疗效及长期结果:前列腺癌治疗方式的全面系统评价和荟萃分析
Cureus. 2024 Apr 23;16(4):e58842. doi: 10.7759/cureus.58842. eCollection 2024 Apr.
5
Comparing pentafecta outcomes between nerve sparing and non nerve sparing robot-assisted radical prostatectomy in a propensity score-matched study.在倾向评分匹配研究中比较保留神经和不保留神经的机器人辅助前列腺根治性切除术的五因素结局。
Sci Rep. 2023 Sep 22;13(1):15835. doi: 10.1038/s41598-023-43092-z.
6
Efficacy and Safety of Neoadjuvant Luteinizing Hormone-Releasing Hormone Antagonist and Tegafur-Uracil Chemohormonal Therapy for High-Risk Prostate Cancer.新辅助促黄体生成素释放激素拮抗剂联合替加氟-尿嘧啶化学激素疗法治疗高危前列腺癌的疗效与安全性
Life (Basel). 2023 Apr 23;13(5):1072. doi: 10.3390/life13051072.
放射组学在调强放疗时代预测放射性毒性中的应用:当前技术水平
Front Oncol. 2020 Oct 6;10:1708. doi: 10.3389/fonc.2020.01708. eCollection 2020.
4
Association between low prostate-specific antigen levels and greater disease progression in high-grade locally-advanced prostate cancer.低前列腺特异性抗原水平与高级别局部晚期前列腺癌疾病进展加剧之间的关联。
J Formos Med Assoc. 2021 Jan;120(1 Pt 2):483-491. doi: 10.1016/j.jfma.2020.06.021. Epub 2020 Jun 23.
5
Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review.高风险局限性和局部进展性前列腺癌的主要治疗方法的获益与风险:一项国际多学科系统评价。
Eur Urol. 2020 May;77(5):614-627. doi: 10.1016/j.eururo.2020.01.033. Epub 2020 Mar 4.
6
Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials.根治性放疗治疗侵袭性前列腺癌后的局部失败和生存:六项随机试验的个体患者水平荟萃分析。
Eur Urol. 2020 Feb;77(2):201-208. doi: 10.1016/j.eururo.2019.10.008. Epub 2019 Nov 10.
7
Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension.根治性前列腺切除术联合辅助放疗与单纯根治性前列腺切除术治疗切缘阳性或包膜外侵犯的前列腺癌患者的随机临床试验。
Eur Urol. 2019 Nov;76(5):586-595. doi: 10.1016/j.eururo.2019.07.001. Epub 2019 Jul 30.
8
Epidemiology of Prostate Cancer.前列腺癌流行病学
World J Oncol. 2019 Apr;10(2):63-89. doi: 10.14740/wjon1191. Epub 2019 Apr 20.
9
Impact of Magnetic Resonance Imaging on Prostate Cancer Staging and European Association of Urology Risk Classification.磁共振成像对前列腺癌分期和欧洲泌尿外科学会风险分类的影响。
Urology. 2019 Aug;130:113-119. doi: 10.1016/j.urology.2019.04.023. Epub 2019 Apr 30.
10
Dose Escalation for Prostate Adenocarcinoma: A Long-Term Update on the Outcomes of a Phase 3, Single Institution Randomized Clinical Trial.前列腺腺癌的剂量递增:一项 3 期单机构随机临床试验结果的长期更新。
Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):790-797. doi: 10.1016/j.ijrobp.2019.02.045. Epub 2019 Mar 2.